Document is current
Any future updates will be listed below
-
Authors
Kawasaki, Kenta
Salehi, Sohrab
Zhan, Yingqian A. https://orcid.org/0000-0002-3548-9227
Chen, Kevin
Lee, Jun Ho
Salataj, Eralda
Zhong, Hong
Manoj, Parvathy
Kinyua, Dennis
Mello, Barbara P. https://orcid.org/0000-0001-6688-8119
Sridhar, Harsha
Tischfield, Sam E. https://orcid.org/0000-0002-5717-3856
Linkov, Irina
Ceglia, Nicholas
Zatzman, Matthew https://orcid.org/0000-0001-5235-4116
Havasov, Eliyahu
Shah, Neil J.
Meng, Fanli
Loomis, Brian https://orcid.org/0000-0002-1863-1199
Bhanot, Umesh K. https://orcid.org/0000-0001-6656-1239
Redin, Esther
de Stanchina, Elisa
Hamard, Pierre-Jacques https://orcid.org/0000-0002-2484-6161
Koche, Richard P. https://orcid.org/0000-0002-6820-5083
McPherson, Andrew https://orcid.org/0000-0002-5654-5101
Quintanal-Villalonga, Álvaro
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
Massagué, Joan https://orcid.org/0000-0001-9324-8408
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35-CA263816, U24-CA213274, P30-CA008748, R35-CA252978)
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 14 May 2025
First Online: 26 May 2025
Competing interests
: A.Q.V. has received honoraria from and is currently fully employed by Astra Zeneca. J.M. holds company stock from Scholar Rock. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Daiichi Sankyo, Genentech/Roche, Jazz, and Merck, and serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics. C.M.R. has received licensing fees and royalties based on DLL3 antibody-based therapeutics. The remaining authors declare no competing interests.
